GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

saroglitazar   Click here for help

GtoPdb Ligand ID: 14341

Synonyms: Bilypsa® | Lipaglyn® | ZYH1
Approved drug PDB Ligand
saroglitazar is an approved drug
Compound class: Synthetic organic
Comment: Saroglitazar (ZYH1) is a liver-selective, peroxisome proliferator-activated receptor (PPAR) agonist; predominantly a PPARα agonist with modest PPARγ activity [3]. It acts via PPARα to lower high blood triglycerides and non-HDL cholesterol, and via PPARγ to improve insulin resistance and regain glycemic control [4,7].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 11
Topological polar surface area 84.3
Molecular weight 439.57
XLogP 3.3
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCO[C@@H](CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
Isomeric SMILES CCO[C@@H](CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
InChI InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1
InChI Key MRWFZSLZNUJVQW-DEOSSOPVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Agrawal R. (2014)
The first approved agent in the Glitazar's Class: Saroglitazar.
Curr Drug Targets, 15 (2): 151-5. [PMID:23906191]
2. Gupta M, Lachhwani H, Chandra KP, Awasthi R, Kumar D. (2026)
Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real-World Assessment of Liver and Metabolic Health.
Endocrinol Diabetes Metab, 9 (1): e70144. [PMID:41450117]
3. Jani RH, Kansagra K, Jain MR, Patel H. (2013)
Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Clin Drug Investig, 33 (11): 809-16. [PMID:24062180]
4. Munigoti SP, Harinarayan CV. (2014)
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?.
Indian J Endocrinol Metab, 18 (3): 283-7. [PMID:24944919]
5. Ragottham K, Mukunda N, Lokesh LV. (2025)
Effect of Addition of Saroglitazar to Lifestyle Modifications in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Observational Study.
Ann Afr Med, [Epub ahead of print]. [PMID:41313090]
6. Roy A, Chakraborty S, Jajodia S, Goenka U, Tewari A, Sonthalia N, Ghoshal UC, Goenka M. (2025)
Impact of Saroglitazar on Liver Stiffness Measurements in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Compensated Cirrhosis: A Single-Arm Study.
Cureus, 17 (9): e92313. [PMID:41103905]
7. Selvarajan S, Nishanthi A, Jayakumar I, Venkatraman S, Shivabasappa S, Sahoo J, Kamalanathan S, George M. (2025)
Effect of Saroglitazar on Glycemic Status: A Meta-analysis.
Cureus, 17 (12): e99122. [PMID:41531617]
8. Yang Y, Zhao Y, Li W, Wu Y, Wang X, Wang Y, Liu T, Ye T, Xie Y, Cheng Z et al.. (2020)
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
Eur J Med Chem, 197: 112311. [PMID:32339855]